Shamburg News · 8-K filed Nov 16, 2026, 4:10 PM EST

ORIC Pharmaceuticals Reports Third Quarter 2026 Financial Results and Program Updates

ORIC · Oric Pharmaceuticals, Inc.

  • Earnings
  • Materiality: high

ORIC Pharmaceuticals reported a net loss of $48,076 thousand, or $(0.44) per share basic and diluted, for the quarter ended September 30, 2026, compared to a net loss of $(32,587) thousand, or $(0.33) per share, for the prior-year quarter. Research and development expenses were $43.4 million for the quarter, and cash, cash equivalents and investments totaled $345.4 million as of September 30, 2026. The company also reported Himalayas-1 and Redwood-1 Phase 3 program updates and an agreement with Cancer Research UK for ORIC-259.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001193125-26-463506.

Written from the filing by Shamburg Markets. Figures are as reported by the company.